These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 1860329)

  • 1. Serum aminoglycoside clearance is predicted as poorly by renal aminoglycoside clearance as by creatinine clearance in critically ill patients.
    Hickling KG; Begg EJ; Perry RE; Atkinson HC; Sharman JR
    Crit Care Med; 1991 Aug; 19(8):1041-7. PubMed ID: 1860329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
    Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
    Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of glomerular filtration rate using aminoglycoside clearance in critically ill medical patients.
    Zarowitz BJ; Robert S; Peterson EL
    Ann Pharmacother; 1992 Oct; 26(10):1205-10. PubMed ID: 1421639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patients.
    Reimann IR; Meier-Hellmann A; Traut T; Reinhart K; Hoffmann A
    Exp Toxicol Pathol; 2003 Jun; 54(5-6):493-8. PubMed ID: 12877363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Serum level-adjusted dosage of once-daily aminoglycoside therapy in critical illness: results of a prospective study].
    Reimann IR; Meier-Hellmann A; Pfeifer R; Traut T; Schilling A; Stein G; Reinhart K; Hoffmann A
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 May; 34(5):288-95. PubMed ID: 10372218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides.
    Matthews I; Kirkpatrick C; Holford N
    Br J Clin Pharmacol; 2004 Jul; 58(1):8-19. PubMed ID: 15206987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens.
    Barletta JF; Johnson SB; Nix DE; Nix LC; Erstad BL
    J Trauma; 2000 Nov; 49(5):869-72. PubMed ID: 11086778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of gentamicin concentrations in critically ill patients: a population pharmacokinetic analysis.
    Hodiamont CJ; Juffermans NP; Bouman CS; de Jong MD; Mathôt RA; van Hest RM
    Int J Antimicrob Agents; 2017 Feb; 49(2):204-211. PubMed ID: 28038961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective randomised trial comparing individualised pharmacokinetic dosage prediction for aminoglycosides with prediction based on estimated creatinine clearance in critically ill patients.
    Hickling K; Begg E; Moore ML
    Intensive Care Med; 1989; 15(4):233-7. PubMed ID: 2745867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simplified monitoring of aminoglycoside treatment.
    Cronberg S; Nordström L
    Scand J Infect Dis Suppl; 1990; 74():274-9. PubMed ID: 2097716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis.
    Lugo G; Castañeda-Hernández G
    Crit Care Med; 1997 May; 25(5):806-11. PubMed ID: 9187600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of aminoglycoside dosing and estimated glomerular filtration rate in determining gentamicin and tobramycin area under the curve and clearance.
    Lim AK; Mathanasenarajah G; Larmour I
    Intern Med J; 2015 Mar; 45(3):319-29. PubMed ID: 25581282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations*.
    Udy AA; Baptista JP; Lim NL; Joynt GM; Jarrett P; Wockner L; Boots RJ; Lipman J
    Crit Care Med; 2014 Mar; 42(3):520-7. PubMed ID: 24201175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of Diet in Renal Disease and modified Cockcroft-Gault formulas in predicting aminoglycoside elimination.
    Bookstaver PB; Johnson JW; McCoy TP; Stewart D; Williamson JC
    Ann Pharmacother; 2008 Dec; 42(12):1758-65. PubMed ID: 19047358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologic response of stress and aminoglycoside clearance in critically ill patients.
    Tholl DA; Shikuma LR; Miller TQ; Woodward JM; Cerra FB; Zaske DE
    Crit Care Med; 1993 Feb; 21(2):248-51. PubMed ID: 8428477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aminoglycoside pharmacokinetics in African-Americans with normal renal function.
    Oparaoji EC; Siram S; Elemihe U; Mezghebe HM; Cho T; Bashiri M; Piedrahita K; Pipalla RS
    J Clin Pharm Ther; 1998 Jun; 23(3):191-7. PubMed ID: 9831970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily.
    Kirkpatrick CM; Duffull SB; Begg EJ
    Br J Clin Pharmacol; 1999 Jun; 47(6):637-43. PubMed ID: 10383541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Altered aminoglycoside pharmacokinetics in critically ill patients with sepsis.
    Mann HJ; Fuhs DW; Awang R; Ndemo FA; Cerra FB
    Clin Pharm; 1987 Feb; 6(2):148-53. PubMed ID: 3665367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variable pharmacokinetics of extended interval tobramycin or gentamicin among critically ill patients undergoing continuous venovenous hemofiltration.
    Chuk AC; Saeed F; Kousar N; Burrill S; Barns B; Rickrode G; Fu J; Katrych O; Saunders-Hao P; Block C; Lahey T
    Clin Nephrol; 2015 Oct; 84(4):214-21. PubMed ID: 26308080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of extended-interval aminoglycoside dosing strategies for the treatment of moderate-to-severe infections encountered in critically ill surgical patients.
    Mueller EW; Boucher BA
    Surg Infect (Larchmt); 2009 Dec; 10(6):563-70. PubMed ID: 20035611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.